Skip to main content

Advertisement

SpringerLink
Log in

Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical efficacy

  • Review Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Oxaliplatin is a third-generation platinum compound approved for clinical use relatively recently as compared to other drugs of the same class. Its main cellular target is DNA, where similarly to cisplatin and carboplatin it forms cross-links. However, due to a unique indication for colorectal cancer, synergistic interaction with fluoropyrimidines and peculiar toxicity profile, oxaliplatin is different from those compounds. Multiple lines of evidence indicate differences in transport and metabolism, consequences of DNA platination, as well as DNA repair and transduction of DNA damage. Here, we explore the preclinical features that may explain the unique properties of oxaliplatin in the clinics. Among them, the capability to accumulate in tumor cells via organic cation transporters, to kill KRAS mutant cells and to activate immunogenic cell death appears helpful to explain in part its clinical behavior. The continuous investigation of the molecular pharmacology of oxaliplatin is expected to provide clues to the definitions of predictors of drug activity and toxicity to translate to the clinical setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Chau I, Cunningham D (2003) Oxaliplatin for colorectal cancer in the United States: better late than never. J Clin Oncol 21:2049–2051

    Article  PubMed  CAS  Google Scholar 

  2. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A, Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343–2351

    Article  PubMed  CAS  Google Scholar 

  3. Fischel JL, Etienne MC, Formento P, Milano G (1998) Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data. Clin Cancer Res 4:2529–2535

    PubMed  CAS  Google Scholar 

  4. Bajetta E, Celio L, Ferrario E, Di Bartolomeo M, Denaro A, Dotti K, Mancin M, Bajetta R, Colombo A, Pusceddu S (2007) Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. Ann Oncol 18:1810–1816

    Article  PubMed  CAS  Google Scholar 

  5. Grothey A, Goetz MP (2004) Oxaliplatin plus oral fluoropyrimidines in colorectal cancer. Clin Colorectal Cancer 4(Suppl 1):S37–S42

    Article  PubMed  CAS  Google Scholar 

  6. Raymond E, Chaney SG, Taamma A, Cvitkovic E (1998) Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 9:1053–1071

    Article  PubMed  CAS  Google Scholar 

  7. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehme A, Christen RD, Howell SB (1996) The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56:4881–4886

    PubMed  CAS  Google Scholar 

  8. Martelli L, Di Mario F, Ragazzi E, Apostoli P, Leone R, Perego P, Fumagalli G (2006) Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells. Biochem Pharmacol 72:693–700

    Article  PubMed  CAS  Google Scholar 

  9. Raymond E, Faivre S, Woynarowski JM, Chaney SG (1998) Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 25:4–12

    PubMed  CAS  Google Scholar 

  10. Cossa G, Gatti L, Zunino F, Perego P (2009) Strategies to improve the efficacy of platinum compounds. Curr Med Chem 16:2355–2365

    Article  PubMed  CAS  Google Scholar 

  11. Vaisman A, Varchenko M, Umar A, Kunkel TA, Risinger JI, Barrett JC, Hamilton TC, Chaney SG (1998) The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 58:3579–3585

    PubMed  CAS  Google Scholar 

  12. Nehme A, Baskaran R, Nebel S, Fink D, Howell SB, Wang JY, Christen RD (1999) Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells. Br J Cancer 79:1104–1110

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  13. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Metivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13:54–61

    Article  PubMed  CAS  Google Scholar 

  14. Screnci D, McKeage MJ, Galettis P, Hambley TW, Palmer BD, Baguley BC (2000) Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs. Br J Cancer 82:966–972

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  15. Sprowl JA, Ness RA, Sparreboom A (2013) Polymorphic transporters and platinum pharmacodynamics. Drug Metab Pharmacokinet 28:19–27

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  16. Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K (2006) Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther 319:879–886

    Article  PubMed  CAS  Google Scholar 

  17. Yokoo S, Yonezawa A, Masuda S, Fukatsu A, Katsura T, Inui K (2007) Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem Pharmacol 74:477–487

    Article  PubMed  CAS  Google Scholar 

  18. Zhang S, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A, Chen Y, Komori T, Gray JW, Chen X, Lippard SJ, Giacomini KM (2006) Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res 66:8847–8857

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  19. Li S, Chen Y, Zhang S, More SS, Huang X, Giacomini KM (2011) Role of organic cation transporter 1, OCT1 in the pharmacokinetics and toxicity of cis-diammine(pyridine)chloroplatinum(II) and oxaliplatin in mice. Pharm Res 28:610–625

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  20. Tashiro A, Tatsumi S, Takeda R, Naka A, Matsuoka H, Hashimoto Y, Hatta K, Maeda K, Kamoshida S (2014) High expression of organic anion transporter 2 and organic cation transporter 2 is an independent predictor of good outcomes in patients with metastatic colorectal cancer treated with FOLFOX-based chemotherapy. Am J Cancer Res 4:528–536

    PubMed  CAS  PubMed Central  Google Scholar 

  21. Jong NN, Nakanishi T, Liu JJ, Tamai I, McKeage MJ (2011) Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons. J Pharmacol Exp Ther 338:537–547

    Article  PubMed  CAS  Google Scholar 

  22. Larson CA, Blair BG, Safaei R, Howell SB (2009) The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs. Mol Pharmacol 75:324–330

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  23. Liu JJ, Jamieson SM, Subramaniam J, Ip V, Jong NN, Mercer JF, McKeage MJ (2009) Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity. Cancer Chemother Pharmacol 64:847–856

    Article  PubMed  CAS  Google Scholar 

  24. Blair BG, Larson CA, Safaei R, Howell SB (2009) Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin. Clin Cancer Res 15:4312–4321

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  25. Samimi G, Katano K, Holzer AK, Safaei R, Howell SB (2004) Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B. Mol Pharmacol 66:25–32

    Article  PubMed  CAS  Google Scholar 

  26. Martinez-Balibrea E, Martinez-Cardus A, Musulen E, Gines A, Manzano JL, Aranda E, Plasencia C, Neamati N, Abad A (2009) Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy. Int J Cancer 124:2905–2910

    Article  PubMed  CAS  Google Scholar 

  27. Ip V, Liu JJ, Mercer JF, McKeage MJ (2010) Differential expression of ATP7A, ATP7B and CTR1 in adult rat dorsal root ganglion tissue. Mol Pain 6:53-8069-6-53

    Article  Google Scholar 

  28. Gatti L, Beretta GL, Cossa G, Zunino F, Perego P (2009) ABC transporters as potential targets for modulation of drug resistance. Mini Rev Med Chem 9:1102–1112

    Article  PubMed  CAS  Google Scholar 

  29. Taniguchi K, Wada M, Kohno K, Nakamura T, Kawabe T, Kawakami M, Kagotani K, Okumura K, Akiyama S, Kuwano M (1996) A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res 56:4124–4129

    PubMed  CAS  Google Scholar 

  30. Gamelin L, Capitain O, Morel A, Dumont A, Traore S, le Anne B, Gilles S, Boisdron-Celle M, Gamelin E (2007) Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin Cancer Res 13:6359–6368

    Article  PubMed  CAS  Google Scholar 

  31. Hinoshita E, Uchiumi T, Taguchi K, Kinukawa N, Tsuneyoshi M, Maehara Y, Sugimachi K, Kuwano M (2000) Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. Clin Cancer Res 6:2401–2407

    PubMed  CAS  Google Scholar 

  32. Mirakhorli M, Shayanfar N, Rahman SA, Rosli R, Abdullah S, Khoshzaban A (2012) Lack of association between expression of MRP2 and early relapse of colorectal cancer in patients receiving FOLFOX-4 chemotherapy. Oncol Lett 4:893–897

    PubMed  CAS  PubMed Central  Google Scholar 

  33. Nigam SK (2015) What do drug transporters really do? Nat Rev Drug Discov 14:29–44

    Article  PubMed  CAS  Google Scholar 

  34. Fletcher JI, Haber M, Henderson MJ, Norris MD (2010) ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 10:147–156

    Article  PubMed  CAS  Google Scholar 

  35. Perego P, Gatti L, Beretta GL (2010) The ABC of glycosylation. Nat Rev Cancer 10:523-c1 (Epub 2010 Jun 10)

    Article  Google Scholar 

  36. Theile D, Grebhardt S, Haefeli WE, Weiss J (2009) Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy. Biochem Pharmacol 78:1366–1373

    Article  PubMed  CAS  Google Scholar 

  37. Mohn C, Hacker HG, Hilger RA, Gutschow M, Jaehde U (2013) Defining the role of MRP-mediated efflux and glutathione in detoxification of oxaliplatin. Pharmazie 68:622–627

    PubMed  CAS  Google Scholar 

  38. Mohn C, Kalayda GV, Hacker HG, Gutschow M, Metzger S, Jaehde U (2010) Contribution of glutathione and MRP-mediated efflux to intracellular oxaliplatin accumulation. Int J Clin Pharmacol Ther 48:445–447

    Article  PubMed  CAS  Google Scholar 

  39. Vekris A, Meynard D, Haaz MC, Bayssas M, Bonnet J, Robert J (2004) Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research. Cancer Res 64:356–362

    Article  PubMed  CAS  Google Scholar 

  40. Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4:307–320

    Article  PubMed  CAS  Google Scholar 

  41. Chaney SG, Campbell SL, Bassett E, Wu Y (2005) Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol 53:3–11

    Article  PubMed  Google Scholar 

  42. Robert J, Laurand A, Meynard D, Le Morvan V (2009) Lessons for the NCI panel and clinical correlates. In: Bonetti A, Leone R, Howell SB (eds) Platinum and other heavy metal compounds in cancer chemotherapy, 2009th edn. Humana Press, New York, pp 149–155

    Chapter  Google Scholar 

  43. He Q, Liang CH, Lippard SJ (2000) Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc Natl Acad Sci USA 97:5768–5772

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  44. Nagatani G, Nomoto M, Takano H, Ise T, Kato K, Imamura T, Izumi H, Makishima K, Kohno K (2001) Transcriptional activation of the human HMG1 gene in cisplatin-resistant human cancer cells. Cancer Res 61:1592–1597

    PubMed  CAS  Google Scholar 

  45. Vaisman A, Chaney SG (2000) The efficiency and fidelity of translesion synthesis past cisplatin and oxaliplatin GpG adducts by human DNA polymerase beta. J Biol Chem 275:13017–13025

    Article  PubMed  CAS  Google Scholar 

  46. Vaisman A, Masutani C, Hanaoka F, Chaney SG (2000) Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase eta. Biochemistry 39:4575–4580

    Article  PubMed  CAS  Google Scholar 

  47. Albertella MR, Green CM, Lehmann AR, O’Connor MJ (2005) A role for polymerase eta in the cellular tolerance to cisplatin-induced damage. Cancer Res 65:9799–9806

    Article  PubMed  CAS  Google Scholar 

  48. Sharma S, Shah NA, Joiner AM, Roberts KH, Canman CE (2012) DNA polymerase zeta is a major determinant of resistance to platinum-based chemotherapeutic agents. Mol Pharmacol 81:778–787

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  49. Yang J, Parsons J, Nicolay NH, Caporali S, Harrington CF, Singh R, Finch D, D’Atri S, Farmer PB, Johnston PG, McKenna WG, Dianov G, Sharma RA (2010) Cells deficient in the base excision repair protein, DNA polymerase beta, are hypersensitive to oxaliplatin chemotherapy. Oncogene 29:463–468

    Article  PubMed  CAS  Google Scholar 

  50. Teng KY, Qiu MZ, Li ZH, Luo HY, Zeng ZL, Luo RZ, Zhang HZ, Wang ZQ, Li YH, Xu RH (2010) DNA polymerase eta protein expression predicts treatment response and survival of metastatic gastric adenocarcinoma patients treated with oxaliplatin-based chemotherapy. J Transl Med 8:126-5876-8-126

    Article  Google Scholar 

  51. Welsh C, Day R, McGurk C, Masters JR, Wood RD, Koberle B (2004) Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int J Cancer 110:352–361

    Article  PubMed  CAS  Google Scholar 

  52. Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC (2003) Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 63:1311–1316

    PubMed  CAS  Google Scholar 

  53. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC, Bio Investigators IALT (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983–991

    Article  PubMed  CAS  Google Scholar 

  54. Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, Vinolas N, Paz-Ares L, Lopez-Vivanco G, Munoz MA, Felip E, Alberola V, Camps C, Domine M, Sanchez JJ, Sanchez-Ronco M, Danenberg K, Taron M, Gandara D, Rosell R (2007) Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 25:2747–2754

    Article  PubMed  CAS  Google Scholar 

  55. Bellmunt J, Paz-Ares L, Cuello M, Cecere FL, Albiol S, Guillem V, Gallardo E, Carles J, Mendez P, de la Cruz JJ, Taron M, Rosell R, Baselga J, Spanish Oncology Genitourinary Group (2007) Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 18:522–528

    Article  PubMed  CAS  Google Scholar 

  56. Jun HJ, Ahn MJ, Kim HS, Yi SY, Han J, Lee SK, Ahn YC, Jeong HS, Son YI, Baek JH, Park K (2008) ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer 99:167–172

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  57. Kim MK, Cho KJ, Kwon GY, Park SI, Kim YH, Kim JH, Song HY, Shin JH, Jung HY, Lee GH, Choi KD, Kim SB (2008) Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy. Clin Cancer Res 14:4225–4231

    Article  PubMed  CAS  Google Scholar 

  58. Bohanes P, Labonte MJ, Lenz HJ (2011) A review of excision repair cross-complementation group 1 in colorectal cancer. Clin Colorectal Cancer 10:157–164

    Article  PubMed  CAS  Google Scholar 

  59. Li P, Fang YJ, Li F, Ou QJ, Chen G, Ma G (2013) ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy. Br J Cancer 108:1238–1244

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  60. Yin M, Yan J, Martinez-Balibrea E, Graziano F, Lenz HJ, Kim HJ, Robert J, Im SA, Wang WS, Etienne-Grimaldi MC, Wei Q (2011) ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin Cancer Res 17:1632–1640

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  61. Tiseo M, Giovannetti E, Tibaldi C, Camerini A, Di Costanzo F, Barbieri F, Burgers JA, Vincent A, Peters GJ, Smit EF, Ardizzoni A (2012) Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin. Lung Cancer 78:92–99

    Article  PubMed  Google Scholar 

  62. Avan A, Pacetti P, Reni M, Milella M, Vasile E, Mambrini A, Vaccaro V, Caponi S, Cereda S, Peters GJ, Cantore M, Giovannetti E (2013) Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back. Int J Cancer 133:1016–1022

    Article  PubMed  CAS  Google Scholar 

  63. Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R, Howell SB (1996) Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56:3087–3090

    PubMed  CAS  Google Scholar 

  64. Brown R, Hirst GL, Gallagher WM, McIlwrath AJ, Margison GP, van der Zee AG, Anthoney DA (1997) hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 15:45–52

    Article  PubMed  CAS  Google Scholar 

  65. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, Ribic C, Grothey A, Moore M, Zaniboni A, Seitz JF, Sinicrope F, Gallinger S (2010) Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28:3219–3226

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  66. Zaanan A, Flejou JF, Emile JF, Des GG, Cuilliere-Dartigues P, Malka D, Lecaille C, Validire P, Louvet C, Rougier P, de Gramont A, Bonnetain F, Praz F, Taieb J (2011) Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy. Clin Cancer Res 17:7470–7478

    Article  PubMed  CAS  Google Scholar 

  67. Maxwell KN, Domchek SM (2012) Cancer treatment according to BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol 9:520–528

    Article  PubMed  CAS  Google Scholar 

  68. Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK, Zhang W (2011) Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 306:1557–1565

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  69. Golan T, Kanji ZS, Epelbaum R, Devaud N, Dagan E, Holter S, Aderka D, Paluch-Shimon S, Kaufman B, Gershoni-Baruch R, Hedley D, Moore MJ, Friedman E, Gallinger S (2014) Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 111:1132–1138

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  70. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ, Couch FJ, Urban N, Taniguchi T (2008) Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451:1116–1120

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  71. Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T (2008) Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 68:2581–2586

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  72. Prewett M, Deevi DS, Bassi R, Fan F, Ellis LM, Hicklin DJ, Tonra JR (2007) Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab. Clin Cancer Res 13:7432–7440

    Article  PubMed  CAS  Google Scholar 

  73. Yacoub A, Park JS, Qiao L, Dent P, Hagan MP (2001) MAPK dependence of DNA damage repair: ionizing radiation and the induction of expression of the DNA repair genes XRCC1 and ERCC1 in DU145 human prostate carcinoma cells in a MEK1/2 dependent fashion. Int J Radiat Biol 77:1067–1078

    Article  PubMed  CAS  Google Scholar 

  74. Flanigan SA, Pitts TM, Eckhardt SG, Tentler JJ, Tan AC, Thorburn A, Leong S (2010) The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models. Clin Cancer Res 16:5436–5446

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  75. Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, van Buren G, Samuel S, Kim MP, Lim SJ, Ellis LM (2009) Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 69:1951–1957

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  76. Patel BB, Sengupta R, Qazi S, Vachhani H, Yu Y, Rishi AK, Majumdar AP (2008) Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. Int J Cancer 122:267–273

    Article  PubMed  CAS  Google Scholar 

  77. Bose D, Zimmerman LJ, Pierobon M, Petricoin E, Tozzi F, Parikh A, Fan F, Dallas N, Xia L, Gaur P, Samuel S, Liebler DC, Ellis LM (2011) Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells. Br J Cancer 105:1759–1767

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  78. Larsen AK, de Gramont A, Poindessous V, Bouygues A, Ayadi M, Mésange P (2013) Functional and clinical implications of autocrine VEGF signaling in colorectal cancer. Curr Colorectal Cancer Rep 9:270–277

    Article  Google Scholar 

  79. Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R, Gray MJ, Cheng H, Hoff PM, Ellis LM (2006) Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 12:4147–4153

    Article  PubMed  CAS  Google Scholar 

  80. Bates RC, Goldsmith JD, Bachelder RE, Brown C, Shibuya M, Oettgen P, Mercurio AM (2003) Flt-1-dependent survival characterizes the epithelial-mesenchymal transition of colonic organoids. Curr Biol 13:1721–1727

    Article  PubMed  CAS  Google Scholar 

  81. Morrow CJ, Ghattas M, Smith C, Bonisch H, Bryce RA, Hickinson DM, Green TP, Dive C (2010) Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters. Cancer Res 70:5931–5941

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  82. Cossa G, Gatti L, Cassinelli G, Lanzi C, Zaffaroni N, Perego P (2013) Modulation of sensitivity to antitumor agents by targeting the MAPK survival pathway. Curr Pharm Des 19:883–894

    Article  PubMed  CAS  Google Scholar 

  83. Benedetti V, Perego P, Luca Beretta G, Corna E, Tinelli S, Righetti SC, Leone R, Apostoli P, Lanzi C, Zunino F (2008) Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds. Mol Cancer Ther 7:679–687

    Article  PubMed  CAS  Google Scholar 

  84. Cossa G, Lanzi C, Cassinelli G, Carenini N, Arrighetti N, Gatti L, Corna E, Zunino F, Zaffaroni N, Perego P (2014) Differential outcome of MEK1/2 inhibitor-platinum combinations in platinum-sensitive and -resistant ovarian carcinoma cells. Cancer Lett 347:212–224

    Article  PubMed  CAS  Google Scholar 

  85. de Bruijn MT, Raats DA, Hoogwater FJ, van Houdt WJ, Cameron K, Medema JP, Borel Rinkes IH, Kranenburg O (2010) Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa. Br J Cancer 102:1254–1264

    Article  PubMed  PubMed Central  Google Scholar 

  86. Toscano F, Parmentier B, Fajoui ZE, Estornes Y, Chayvialle JA, Saurin JC, Abello J (2007) P53 dependent and independent sensitivity to oxaliplatin of colon cancer cells. Biochem Pharmacol 74:392–406

    Article  PubMed  CAS  Google Scholar 

  87. Wilson C, Purcell C, Seaton A, Oladipo O, Maxwell PJ, O’Sullivan JM, Wilson RH, Johnston PG, Waugh DJ (2008) Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kappaB transcription and evasion of apoptosis. J Pharmacol Exp Ther 327:746–759

    Article  PubMed  CAS  Google Scholar 

  88. Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, Taylor G, Barrett JH, Quirke P (2009) KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 27:5931–5937

    Article  PubMed  CAS  Google Scholar 

  89. Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, Silver J, Ogino S, Hooshmand S, Kwak E, Freed E, Meyerhardt JA, Saridaki Z, Georgoulias V, Finkelstein D, Fuchs CS, Kulke MH, Shivdasani RA (2009) Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer 101:465–472

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  90. Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, Mariette C, Chaput N, Mira JP, Delaloge S, Andre F, Tursz T, Kroemer G, Zitvogel L (2007) The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 220:47–59

    Article  PubMed  CAS  Google Scholar 

  91. Martins I, Wang Y, Michaud M, Ma Y, Sukkurwala AQ, Shen S, Kepp O, Metivier D, Galluzzi L, Perfettini JL, Zitvogel L, Kroemer G (2014) Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ 21:79–91

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  92. Vacchelli E, Aranda F, Obrist F, Eggermont A, Galon J, Cremer I, Zitvogel L, Kroemer G, Galluzzi L (2014) Trial watch: immunostimulatory cytokines in cancer therapy. Oncoimmunology 3:e29030

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

PP is in part supported by the Associazione Italiana per la Ricerca sul Cancro, Milan, and by Fondazione I. Monzino, Italy. JR is partially supported by the Ligue nationale contre le Cancer. This study was also performed on behalf of the EORTC-PAMM group.

Author information

Authors and Affiliations

  1. Molecular Pharmacology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Amadeo 42, 20133, Milan, Italy

    Paola Perego

  2. INSERM U916, Institut Bergonié, University of Bordeaux, 229 Cours de l’Argonne, 33000, Bordeaux, France

    Jacques Robert

Authors
  1. Paola Perego
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jacques Robert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paola Perego.

Ethics declarations

Conflict of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Perego, P., Robert, J. Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical efficacy. Cancer Chemother Pharmacol 77, 5–18 (2016). https://doi.org/10.1007/s00280-015-2901-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-015-2901-x

Keywords

Search

Navigation